Daiwa Securities Group Inc. Has $22.98 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Daiwa Securities Group Inc. reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 29,771 shares of the biopharmaceutical company’s stock after selling 2,058 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $22,979,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. WPG Advisers LLC increased its position in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares during the period. Board of the Pension Protection Fund acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $31,000. Entrust Financial LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $32,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Finally, FNY Investment Advisers LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $38,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on REGN. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Barclays decreased their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Finally, Royal Bank Of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a research report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $792.65.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
• Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
• Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Regeneron Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ REGN opened at $635.45 on Friday. The firm has a market cap of $67.18 billion, a PE ratio of 15.48, a P/E/G ratio of 1.38 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 12-month low of $485.00 and a 12-month high of $821.11. The company’s fifty day simple moving average is $706.93 and its 200 day simple moving average is $742.16. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the firm earned $8.22 earnings per share. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.